TAC-001
- Generic Name
- TAC-001
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Tallac Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT05399654
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸NEXT Oncology- Virginia, Fairfax, Virginia, United States
🇺🇸University of Southern California (USC), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath